NCT03257215 (D-Vex) is a Phase 4 clinical trial of Stoss vitamin D in Atopic Dermatitis, sponsored by Murdoch Childrens Research Institute.

Who is sponsoring NCT03257215?

NCT03257215 is sponsored by Murdoch Childrens Research Institute.

What drugs are being tested in NCT03257215?

Interventions in NCT03257215: Stoss vitamin D, Daily vitamin D, Stoss placebo, Daily placebo.

What condition does NCT03257215 study?

NCT03257215 studies Atopic Dermatitis.

Is NCT03257215 still recruiting?

NCT03257215 is currently terminated. Last updated 14 March 2025.

Last reviewed 2025-03-14 · How we verify

NCT03257215: D-Vex

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Can Vitamin D Treatment Help Treat Moderate to Severe Atopic Dermatitis in Young Children? the D-Vex Pilot Study

Terminated Phase 4 Last updated 14 March 2025

What this trial tests

Phase 4 trial testing Stoss vitamin D in Atopic Dermatitis in 13 participants. Terminated before completion.

Timeline

16 October 2017

Primary endpoint
30 January 2025

30 January 2025

Quick facts

Lead sponsor	Murdoch Childrens Research Institute
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	13
Start date	16 October 2017
Primary completion	30 January 2025
Estimated completion	30 January 2025
Sites	1 location across Australia

Drugs / interventions tested

Stoss vitamin D — full drug profile →
Daily vitamin D — full drug profile →
Stoss placebo — full drug profile →
Daily placebo — full drug profile →

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

Murdoch Childrens Research Institute

Who can join

Adults 1 to 12, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vitamin D is known to have a regulatory influence on both the immune system and skin barrier function. Studies in paediatric populations have found an inverse association of vitamin D levels and with both prevalence and severity of atopic dermatitis (AD). Trials of vitamin D as a treatment for AD are limited in number and size. There has never been a placebo-controlled randomised controlled trial of stoss high dose versus daily standard dose for the treatment of AD. Further, no trials have explored the presence of vitamin D pathway genes and response to treatment of AD. This pilot study will be used as a reference to determine outcomes and feasibility for undertaking a larger and more in depth definitive study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Challenge of Managing Atopic Dermatitis in the United States.
Feldman SR, Cox LS, Strowd LC, Gerber RA, et al · · 2019 · cited 33× · PMID 31057694

Verify or expand the search:

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Other Murdoch Childrens Research Institute trials

Trials by the same sponsor.

NCT07251790 — Optimising Breathing Support at Extubation in Very Preterm Infants: A Clinical Study · NA · not yet recruiting
NCT07136584 — SOS for Caregiver Wellbeing · NA · recruiting
NCT06686446 — Allergic Rhinitis Improvement Through Strategic Education: The ARISE Trial · NA · terminated
NCT06992141 — A Strep Throat Controlled Human Infection Trial in Healthy Adults · EARLY_PHASE1 · completed
NCT06186141 — Nausea and Vomiting in Postoperative Paediatric Patients With Patient-Controlled Analgesia (PCA): Morphine vs Oxycodone · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03257215 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Murdoch Childrens Research Institute
Last refreshed: 14 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03257215.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing